TSThomas M. Schiele

Thomas M. Schiele

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas M. Schiele has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Karl Theisen

    Cardiology Division, Department of Medicine, Munich, Germany

    5 shared publications
  • Uwe Siebert

    Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT TIROL - University for Health Sciences and Technology, Hall in Tirol, Austria

    5 shared publications
  • Volker Klauss

    Ludwig-Maximilians-Universitat Munchen – Innenstadt, Department of Cardiology, University Hospital, Ziemssenstrasse 1, 80336 Minchen, Germany

    5 shared publications
  • Barbara Pöllinger

    Department of Radiation Therapy and Radiation Oncology, Medizinische Klinik und Poliklinik–Innenstadt, University Hospital, Munich, Germany

    3 shared publications
  • Eckhart Dühmke

    Department of Radiation Therapy and Radiation Oncology, Medizinische Klinik und Poliklinik–Innenstadt, University Hospital, Munich, Germany

    3 shared publications
  • Johannes Rieber

    Cardiology Division, Department of Medicine, Munich, Germany

    3 shared publications

Latest Publications

  • Vascular restenosis – striving for therapy

    by Thomas M Schiele, Florian Krötz, Volker Klauss

    Restenosis is the limiting entity following coronary angioplasty. It is associated with significant morbidity, mortality and cost, and thus represents a major clinical and economical problem. Despite technical improvements, restenosis after conventional balloon angioplasty occurs in 30 - 60% of cases. Coronary stenting was able to reduce the incidence by approximately 30%; nevertheless, some 250,000 patients experience in-stent restenotic lesions/year worldwide. In-stent restenosis has been recognised as very difficult to manage, with a repeat restenosis rate of 50%, regardless of the angioplasty device used. So far, only vascular brachytherapy has convincingly reduced the incidence of repeat in-stent restenosis (by 50%) and thus, has emerged as the gold standard of therapy. The introduction of drug-eluting stents has shown a great deal of promise for the treatment of both de novo and restenotic lesions, with reported restenosis rates of < 10%, and benefit for virtually all patient subsets at a higher risk of restenosis. This review outlines the pathophysiology, epidemiology and predictors of the restenosis process, and places emphasis on the various treatment options for its prevention and therapy.


  • Evolution of angiographic restenosis rate and late lumen loss after intracoronary beta radiation for In-Stent restenotic lesions

    by Thomas M Schiele, Barbara Pöllinger, Ralf Kantlehner, Johannes Rieber, Andreas König, Viktória Seelig, Florian Krötz, Hae-Young Sohn, Uwe Siebert, Eckhart Dühmke, et al.


    • 1 January 2004
      • Vol. 16  (1) , 14-9

    Impact of barotrauma on acute and late angiographic and clinical outcomes following angioplasty and beta-irradiation of coronary in-stent restenotic lesions.

    by Thomas M Schiele, Andreas König, Johannes Rieber, Flovian Krötz, Hae-Young Sohn, Ralf Kantlehner, Barbara Pöllinger, Eckhart Dühmke, Karl Theisen, Uwe Siebert, et al.

    The aim of this study was to prospectively evaluate the impact of different degrees of vessel barotrauma on the acute and 1-year clinical and angiographic outcomes of percutaneous coronary intervention (PCI) and adjunctive vascular brachytherapy (VBT) with 90Sr/90Y for in-stent restenotic lesions (ISR) in 118 patients. Sixty consecutive patients were treated according to an aggressive PCI strategy (group 1); fifty-eight were treated non-aggressively (group 2). Irradiation was performed with a manual afterloader. Clinical and angiographic baseline characteristics did not differ between groups. Group 1 yielded a higher acute lumen gain (2.3 +/- 1.2 mm versus 1.7 +/- 1.3 mm; p=0.005) and a higher prevalence of additional stent implantation (48.3% versus 22.4%; p=0.003). At follow-up, net gain (1.8 +/- 0.7 mm versus 1.4 +/- 0.8 mm; p=0.102) was equalized by a higher late loss in group 1 (0.6 +/- 0.8 mm versus 0.3 +/- 0.7 mm; p=0.036). Remaining target vessel late loss, due to edge effects, was considerably higher in group 1 than in group 2 (0.5 +/- 0.8 mm versus 0.2 +/- 0.5 mm; p<0.001), leading to a higher rate of binary angiographic restenosis (23.3% versus 6.9%; p=0.013) and target vessel revascularization (16.7% versus 5.2%; p=0.046). After excluding patients who received additional stents, the angiographic differences between groups were attenuated. Our study does not support the use of oversized balloons and high inflation pressures for the treatment of ISR when combined with VBT. Additional stent implantation combined with VBT carries a high risk of repeat revascularization in the setting of ISR and should be avoided.

  • Comparison of pressure measurement, dobutamine contrast stress echocardiography and SPECT for the evaluation of intermediate coronary stenoses. The COMPRESS trial

    by Johannes Rieber, Philip Jung, Isabelle Erhard, Andreas Koenig, M. Hacker, Thomas M. Schiele, Tobias Segmiller, Hans-Ulrich Stempfle, K. Theisen, U. Siebert, et al.

    BACKGROUND: DSE and SPECT are two well-established methods to non-invasively investigate the functional significance of coronary artery stenoses in patients with coronary artery disease. The measurement of Fractional Flow Reserve has emerged a new invasive reference standard for lesion specific quantification of coronary artery stenoses. The objective of our prospective study was to compare sensitivity and specificity of Dobutamine Stress Echocardiography (DSE) and Single Photon Emission Computer tomography (SPECT) with the pressure derived Frational Flow Reserve (FFR) for the identification of hemodynamic relevant cororonary lesions in patients with predominantely coronary multivessel disease and angiographically intermediate stenoses. METHODS: Inclusion criteria were a coronary lesion of 50-75% diameter stenosis by visual assessment in patients with known or suspected CAD. SPECT, DSE and FFR testing was performed within one week of coronary angiography RESULTS: The study comprised 48 consecutive symptomatic patients. In 41 cases, a coronary multivessel disease was present. Mean FFR was 0.80 ± 0.13 (0.41-1.0). Overall sensitivity of DSE and SPECT was 67% and 69% whereas specificity reached 77% and 87%. However, sensitivity was significantly reduced if the target lesion was located distally. DSE showed poor results if the lesions were located in the circumflex artery or if a history of prior myocardial infarctions was present. CONCLUSION: DSE and SPECT are both useful methods for the non-invasive assessment of coronary artery disease. DSE showed reasonable combination of sensitivity and specificity even in patients with multivessel disease. Although use of noninvasive stress tests is only limited in patients with prior myocardial infarctions and invasive stress testing should be preferred in these patients. (Int J Cardiovasc Intervent 2004; 6: 142-147)


  • Large right atrial thrombus formation originating from a PFO occluder device

    by Johannes Rieber, Thomas M. Schiele, Andreas König, Tanja Limmert, Karl Theisen, Hans‐Ulrich Stempfle, Volker Klauss


  • Open Access

    Clinical and angiographic acute and follow up results of intracoronary beta brachytherapy in saphenous vein bypass grafts: a subgroup analysis of the multicentre European registry of intraluminal coronary beta brachytherapy (RENO)

    by T M Schiele, E Regar, S Silber, E Eeckhout, D Baumgart, W Wijns, A Colombo, W Rutsch, D Meerkin, A Gershlick, et al.

    Objective: To assess clinically and angiographically the feasibility, safety, and effectiveness of vascular brachytherapy (VBT) in saphenous vein bypass grafts (SVG). Patients and methods: 67 of 1098 (6.1%) consecutive patients of the European registry of intraluminal coronary β brachytherapy underwent treatment for 68 SVG lesions by VBT using a Sr/Y90 source train (BetaCath). Clinical follow up data were obtained for all of them after a mean (SD) of 6.3 (2.4) months and angiographic follow up was performed in 61 patients (91.0%) after 6.9 (2.0) months. Results: 58 (86.6%) patients were men, their mean (SD) age was 66 (10) years, 28 (41.8%) had unstable angina, and 21 (31.3%) had diabetes. Fifty three (77.9%) lesions were in-stent restenosis, 13 (19.1%) de novo lesions, and 2 (3.0%) non-stented restenotic lesions. Mean (SD) reference diameter before the intervention was 4.19 (0.52) mm, mean (SD) lesion length was 23.56 (20.38) mm, and mean (SD) minimum lumen diameter measured 0.73 (0.62) mm. Mean (SD) acute gain was 3.02 (0.88) mm. The prescribed radiation dose was 20.1 (3.2) Gy. Pullback manoeuvres were performed in 17 (25.0%) of cases. Most patients received combined aspirin and thienopyridin treatment for 6 or 12 months after the procedure. Technical success was obtained in 62 (91.2%) treated lesions and in-hospital major adverse cardiac events occurred in 4.5%. At follow up, mean (SD) reference diameter was 4.20 (0.53) mm, minimum lumen diameter 2.94 (1.50) mm, and late loss 0.86 (1.25) mm. The overall major adverse cardiac events rate was 26.7%. Conclusion: VBT of SVG is feasible and safe. At follow up the reintervention rate and cardiac morbidity and mortality seem to be favourable, considering that interventions in SVG usually are associated with the highest risks.


  • Klinischer und angiographischer Ein-Jahres-Verlauf nach vaskulärer Beta-Brachytherapie von Instent-Restenosen mit sehr hohem Rezidivrisiko

    by T. M. Schiele, B. Pöllinger, R. Kantlehner, E. Dühmke, K. Theisen, V. Klauss

    Hintergrund und Fragestellung: In randomisierten Studien konnte gezeigt werden, dass eine vaskuläre Brachytherapie (VBT) das Risiko einer Reintervention oder unerwünschter kardialer Ereignisse nach Angioplastie minimiert. Daten zu Subkollektiven mit sehr hohem Restenoserisiko über größere Beobachtungszeiträume hinweg liegen nicht vor. Ziel der Studie war die Charakterisierung von Durchführbarkeit, Sicherheit und Effektivität einer Beta-VBT bei diffusen Instent-Rezidivstenosen (ISR) mit hohem Rezidivrisiko über einen Zeitraum von 12 Monaten. Patienten und Methodik: Bei 79 Patienten wurde eine VBT mit 90Yttrium/Strontium oder 32Phosphor über ein Afterloading-System durchgeführt. Nach 6 Monaten und einem Jahr erfolgten klinische und angiographische Verlaufskontrollen. Ergebnisse: Die Patienten wiesen in 44,4 % eine koronare Dreigefäßerkrankung und eine hohe Prävalenz kardiovaskulärer Risikofaktoren und Komorbidität auf. Die Läsionslänge betrug im Mittel 36,8±18,9 mm. Nach erfolgreicher VBT, wobei in 2,5 % eine Fraktionierung der VBT erforderlich war, konnte bei allen Patienten ein Zugewinn an koronarem Durchmesser von 2,15±0,89 mm gemessen werden. Hierbei erlitt ein Patient in der Hospitalphase einen nicht VBT-assoziierten Myokardinfarkt (AMI). Nach 6 Monaten wurde ein mittlerer Durchmesserverlust von 0,39±0,47 mm und eine Restenoserate der Zielläsion von 16,8 % gemessen. In 18,9 % erfolgte eine erneute Revaskularisation des Zielgefäßes. Nach dieser Zeit waren noch alle Patienten am Leben, drei erlitten jedoch einen AMI nach Absetzen der Clopidogrel-Medikation, wovon einer asymptomatisch verlief. Nach einem Jahr betrug der Durchmesserverlust 0,60 ± 0,56 mm, und die Restenoserate der Zielläsion war auf 33,5 % angestiegen. Die Revaskularisationsrate des Zielgefäßes betrug 26,2 %. Im Ein-Jahres-Verlauf erlitten zwei Patienten einen AMI, und ein Patient verstarb an myokardialem Pumpversagen. Folgerung: Eine Beta-VBT bei Patienten mit hohem Restenoserisiko ist in der Durchführung sicher. Die klinischen und angiographischen Resultate nach einem Jahr fallen zwar gegenüber den 6-Monats-Ergebnissen ab, sind jedoch gegenüber historischen Vergleichsgruppen, die keiner VBT unterzogen wurden, immer noch sehr günstig. Background: Vascular brachytherapy (VBT) has been proven to reduce restenosis rate and unwanted cardiac events in several randomized trials. Long-term data on populations at high risk for re-interventions are few. The aim of this study was to assess the acute and one-year outcome of beta-radiation in coronary in-stent restenoses with a high likelihood of recurrence. Methods: In 79 patients, VBT using 90Yttrium/Strontium or 32Phosphorus, was performed. Clinical and angiographic follow-up was carried out after 6 months and 1 year. Results: 44.4 % of patients had three-vessel coronary artery disease and a high prevalence of cardiovascular risk factors and comorbidity. Mean lesion length was 36.8±18.9 mm. VBT was successful in all patients. Fractionation of VBT was necessary in 2,5 %. Acute gain of luminal diameter was 2.15±0.89 mm. During the hospital stay one acute myocardial infarction (AMI) not associated with VBT occurred. After 6 months loss of luminal diameter measured 0.39±0.47 mm, equaling a restenosis rate (RR) of 16.8 % (1 year: 0.60±0.56 mm, RR 33.5 %). 18.9 % of patients required revascularization of the target lesion (1 year: 29.5 %). After 6 months, all patients survived, three had an AMI after discontinuation of clopidogrel, one of them was asymptomatic (1 year: 1 cardiac death, 2 symptomatic AMI). Conclusion: Beta-VBT in patients at a high risk for recurrence after angioplasty is feasible and safe. Though the clinical and angiographic results at 1 year showed some impairment as opposed to the 6-months-follow-up, they nevertheless are largely superior to those patients from historic controls not treated with VBT.

    • 1 April 2003
      • Vol. 15  (4) , 224-6

    Morphological and functional assessment of the septal course of a left coronary artery originating from the right sinus of valsalva in a heart transplant patient.

    by Thomas M Schiele, Christof Weber, Volker Klauss

    A septal course of the left main coronary artery originating from the right sinus of Valsalva is a rare coronary anomaly of unknown clinical significance. We report on the morphological and functional assessment of this coronary anomaly detected incidentally in a 53-year-old asymptomatic man after orthotopic heart transplantation.

  • Safety and mechanisms of intracoronary manual stepping brachytherapy as gained from serial angiographic and intravascular ultrasound studies.

    by Thomas M Schiele, Andreas König, Andrea Zimmermann, Florian Krötz, Hae-Young Sohn, Johannes Rieber, Ralf Kantlehner, Barbara Pöllinger, Eckhart Dühmke, Karl Theisen, et al.


  • Septal Course of the Left Main Coronary Artery Originating From the Right Sinus of Valsalva

    by Thomas M. Schiele, Christof Weber, Johannes Rieber, Andreas KönIg, Karl Theisen, Gerda Leinsinger, Bruno Reichart, Volker Klauss